Effect of bioflavonoid quercetin on the course of inflammatory process in herpetic keratitis patients with dry eye syndrome 

S. Ya. Rafalyuk

Danylo Halytsky Lviv National Medical University

Lviv, Ukraine

E-mail: sofiyaeye@ukr.net

Backup: The problem of dry eye syndrome is of great importance and significance in ophthalmology.

The purpose of the present paper was to study the effect of Lipoflavon on the course of inflammatory process in herpetic keratitis (HK ) patients with dry eye syndrome (DES).  

Material and Methods: Clinical study was performed in 40 patients with HK (superficial dendritic keratitis) and DES; additionally, we followed up 17 patients with HK. All patients were divided into two groups: Study Group included 15 HK and DES patients receiving Lipoflavon treatment; Control Group included 25 HK and DES patients receiving traditional treatment. The state of the cornea was scored by Draize criteria. The data obtained were statistically processed using SPSS 11.0 package.

Results: Assessing the data obtained in the present study, it is arguable that Lipoflavon significantly decreases clinical signs in patients with HK and DES. 

Conclusions: Inclusion of Lipoflavon in the complex treatment of HK patients with DES significantly increases the efficacy of therapy that is evidenced by the fact that corneal epithelization and infiltrate dispersion are accelerated, and corneal edema and epitheliopathy of the cornea and conjunctiva are less apparent after treatment of patients in Study group as compared to control. The use of quercetin has a positive effect on qualitative and quantitative characteristics of tear production in patients with HK and DES, in particular, Schirmer test values are increased, tear break-up time is increased, conjunctival fold intensity is decreased and tear meniscus height is increased.

Key words: herpetic keratitis, dry eye syndrome, cornea, clinical signs, Lipoflavon


  1. Wilson SE, Netto M, Ambrosio R. Corneal cells: chatty in development, homeoatasis, wound healing, and disease. Am. J. Ophthalmol. 2003; 136: 530-6.
    Crossref   Pubmed
  2. Skripnik RL, Skripnichenko ID. New development in the treatment of dry eye syndrome. Ukr. Med. Chasopys. 2011;1(81):79-80. Russian.
  3. Bourcier T, Borderie V. Decreased corneal sensitivity in patients with dry eye. Invest. Ophthalmol. Vis. Sci. 2005;46:2341-5.
    Crossref   Pubmed
  4. Brzheskii VV. [Tactics of medicamental treatment of patients with various clinical forms of dry eye syndrome]. Klinicheskaia oftalmologiia. 2008;1:4-6. Russian. 
  5. Drozhzhina GI. [Modern methods of treatment of the dry eye syndrome]. Oftalmol Zh.2013;5;89-95. Russian.
  6. Baudouin C. The pathology of dry eye. Surv. Ophthalmol. 2001; 45: S211-S220.
    Crossref   Pubmed
  7. Begley CG, Chalmers RL, Abetz L. The relationship between habitual patient-reported symptoms and clinical signs among patients with dry eye of varying severity. Invest. Ophthalmol. Vis. Sci. 2003;44:4753-61.
    Crossref   Pubmed
  8. Javadi MA, Feizi S. Dry Eye Syndrome. J. Ophthalmic. Vis. Res. 2011;6:192-8.
  9. Gaydamaka TB, Rafalyuk SYa. [Effect of lipoflavon on the activity of redox enzymes in the tear fluid in keratitis in patients with dry eye syndrome].  Ophthalmology. 2016;13(1):4-9. Russian.
  10. Nasledov A. [SPSS computer analysis of data in psychology and social studies]. St.-Petersburg: Piter Publ. 2005:416. Russian.